The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...

TG-C is a novel, off-the-shelf cell and gene therapy designed to slow OA progression and provide a non-surgical alternative to standard of care therapies.

For those ultimately able to fill the prescription, study revealed treatment was delayed by 12 days on average.

Mean total annual payment increased from $4936 to $6722 and from $2651 to $6811 for those with and without diabetes, respectively.

A new pilot program uses regulated prediction markets and independent data verification to establish public probabilities for ...

Higher diagnostic accuracy reported for dementia experts vs primary care doctors before disclosure of test results, but not after.

HT2A receptor inverse agonist advances in clinical development, with phase 2 trial results anticipated in late 2026.

Most obesity drugs do not improve quality of life or heart health, according to a review published online July 8 in The BMJ.

Phase 1/2 DELIVER data demonstrated statistically significant dystrophin expression, functional improvements, and a favorable safety profile with z-rostudirsen.

Clinicians should maintain a high index of suspicion for Cyclospora in patients presenting with prolonged or relapsing watery diarrhea this summer.

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.